Regulation of apoptosis in prostatic disease

Recent studies suggest that aberrant regulation of apoptosis, including acquired apoptosis resistance, contributes to perturbations in cell growth that, in part, underlie the development of benign prostatic hyperplasia (BPH) and prostate cancer. Importantly, apoptosis resistance can enhance the malignant properties of prostate cancer cells, contributing to their widespread metastatic activities. Since apoptosis resistance likely contributes to benign and malignant prostate disease, the promotion of apoptosis represents a reasonable therapeutic objective.

This brief review focuses on the role of apoptosis in prostatic disease and discusses potential intervention points for novel therapeutics.

Novel therapies for prostatic disease, including gene therapy and biological therapy that involve apoptosis as a mechanism of action, are being developed and tested. Ultimately, the identification of proapoptotic and antiapoptotic genes and the pathways through which they operate will serve to provide more rational approaches for further development of more efficacious therapeutic strategies for benign and malignant prostatic disease.